0|chunk|Open Access RESEARCH Treatment with Imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
0	5	11 Access	Chemical	CHEBI_34922
0	36	45 Imiquimod	Chemical	CHEBI_36704
0	101	104 DNA	Chemical	CHEBI_16991
0	CHEBI-CHEBI	CHEBI_34922	CHEBI_36704
0	CHEBI-CHEBI	CHEBI_34922	CHEBI_16991
0	CHEBI-CHEBI	CHEBI_36704	CHEBI_16991

1|chunk|Background: There is an urgent need to develop new innovative therapies for the control of advanced cancer. The combination of antigen-specific immunotherapy with the employment of immunomodulatory agents has emerged as a potentially plausible approach for the control of advanced cancer.

2|chunk|Methods: In the current study, we explored the combination of the DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus type 16 (HPV-16) E7 antigen (CRT/E7) with the TLR7 agonist imiquimod for their ability to generate E7-specific immune responses and antitumor effects in tumor-bearing mice.
2	66	69 DNA	Chemical	CHEBI_16991
2	101	104 CRT	Chemical	CHEBI_23080
2	157	164 antigen	Chemical	CHEBI_59132
2	166	169 CRT	Chemical	CHEBI_23080
2	188	195 agonist	Chemical	CHEBI_48705
2	196	205 imiquimod	Chemical	CHEBI_36704
2	CHEBI-CHEBI	CHEBI_16991	CHEBI_23080
2	CHEBI-CHEBI	CHEBI_16991	CHEBI_59132
2	CHEBI-CHEBI	CHEBI_16991	CHEBI_48705
2	CHEBI-CHEBI	CHEBI_16991	CHEBI_36704
2	CHEBI-CHEBI	CHEBI_23080	CHEBI_59132
2	CHEBI-CHEBI	CHEBI_23080	CHEBI_48705
2	CHEBI-CHEBI	CHEBI_23080	CHEBI_36704
2	CHEBI-CHEBI	CHEBI_59132	CHEBI_48705
2	CHEBI-CHEBI	CHEBI_59132	CHEBI_36704
2	CHEBI-CHEBI	CHEBI_48705	CHEBI_36704

3|chunk|We observed that treatment with CRT/E7 DNA in combination with imiquimod leads to an enhancement in the E7-specific CD8+ T cell immune responses and a decrease in the number of myeloid-derived suppressor cells in the tumor microenvironment of tumor-bearing mice. Furthermore, treatment with CRT/E7 DNA in combination with imiquimod leads to significantly improved antitumor effects and prolonged survival in treated mice. In addition, treatment with imiquimod led to increased number of NK1.1+ cells and F4/80+ cells in the tumor microenvironment. Macrophages and NK1.1+ cells were found to play an important role in the antitumor effects mediated by treatment with CRT/E7 DNA in combination with imiquimod.
3	39	42 DNA	Chemical	CHEBI_16991
3	63	72 imiquimod	Chemical	CHEBI_36704
3	298	301 DNA	Chemical	CHEBI_16991
3	322	331 imiquimod	Chemical	CHEBI_36704
3	450	459 imiquimod	Chemical	CHEBI_36704
3	609	613 role	Chemical	CHEBI_50906
3	673	676 DNA	Chemical	CHEBI_16991
3	697	706 imiquimod	Chemical	CHEBI_36704
3	CHEBI-CHEBI	CHEBI_16991	CHEBI_36704
3	CHEBI-CHEBI	CHEBI_16991	CHEBI_50906
3	CHEBI-CHEBI	CHEBI_36704	CHEBI_50906

4|chunk|Conclusions: Thus, our data suggests that the combination of therapeutic HPV DNA vaccination with topical treatment with the TLR7 agonist imiquimod enhances the antitumor immunity induced by DNA vaccination. The current study has significant implications for future clinical translation.
4	77	80 DNA	Chemical	CHEBI_16991
4	130	137 agonist	Chemical	CHEBI_48705
4	138	147 imiquimod	Chemical	CHEBI_36704
4	191	194 DNA	Chemical	CHEBI_16991
4	CHEBI-CHEBI	CHEBI_16991	CHEBI_48705
4	CHEBI-CHEBI	CHEBI_16991	CHEBI_36704
4	CHEBI-CHEBI	CHEBI_48705	CHEBI_36704

